• EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion’s AI-Immunology™ platform
  • Glioblastoma is characterized by high mortality rates and significant unmet medical needs. EVX-05 is being developed as a novel therapeutic approach to treat glioblastoma
  • Evaxion is collaborating with a world-leading academic medical research institution, which is expected to conduct initial clinical testing of EVX-05
  • Evaxion maintains its cash runway into second half of 2027 as its R&D pipeline is refocused with the addition of EVX-05 while the EVX-03 program is discontinued

COPENHAGEN, Denmark, August 17, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, expands it pipeline of cancer vaccine programs with EVX-05 against the deadly brain cancer glioblastoma.

We are collaborating with experts from Duke University School of Medicine to develop EVX-05. This program targets endogenous retrovirus (ERV)-derived antigens shared between glioblastoma patients, which AI-Immunology™ has unique capabilities in identifying. These ERV-antigens constitute a novel source of highly attractive targets for off-the-shelf cancer vaccines.

With its new therapeutic concept, EVX-05 is being developed as a novel therapeutic approach for glioblastoma. Current therapies are often inadequate, meaning glioblastoma remains one of the most aggressive and deadly cancers.